About MDL 1871
|This Multidistrict Litigation ("MDL") was created by Order of the United States Judicial Panel on Multidistrict Litigation ("MDL Panel") on October 16, 2007. The typical case involves claims by a plaintiff from anywhere in the United States against defendant SmithKlineBeecham Corp., doing business as GlaxoSmithKline ("GSK").
In its October 16, 2007 Order, the MDL Panel found that the actions in this MDL "involve common questions of fact, and that centralization . . . in the Eastern District of Pennsylvania will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation."
The MDL Panel noted that the actions "arise from allegations that certain diabetes drugs manufactured by GSK -- Avandia and/or two sister drugs containing Avandia (Avandamet and Avandaryl) -- cause an increased risk of heart attack and other physical injury, and that GSK failed to provide adequate warnings concerning that risk." GSK denies these allegations. The Panel further found that "centralization . . . will eliminate duplicative discovery, avoid inconsistent rulings, and conserve the resources of the parties, their counsel and the judiciary."